Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
On April 4, 2023, Codexis announced that Patrick Yang, PhD, will not seek re-election to its Board of Directors after serving since 2014. Yang, who chaired the Nominating and Corporate Governance Committee, was recognized for his significant contributions to the company. The Board expressed gratitude for his leadership during his tenure. Codexis noted that Yang's departure comes after strengthening the Board with new members experienced in biomanufacturing and gene therapy. Dr. Yang expressed confidence in Codexis's future under its current leadership, highlighting the company's transformation in Life Sciences and Biotherapeutics.
- Strengthened Board of Directors with new members experienced in biomanufacturing and gene therapy.
- Patrick Yang's departure allows for fresh perspectives in leadership.
- Potential concerns about continuity and experience gaps following Yang's exit.
REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee.
“It has been a privilege to have Pat on the Codexis Board. His expertise in technical operations and manufacturing has been of tremendous value to the company,” said Byron Dorgan, MBA, Chairman of the Board of Directors of Codexis. “On behalf of the Board and the Management Team at Codexis, I would like to thank Pat for his thoughtful guidance and leadership over his nine years of service on the Board, which has helped propel the company to where it is today.”
“We are particularly grateful that Pat’s decision comes after we have further strengthened our Board of Directors,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis. “With Pat’s partnership, we have ensured continuity of Board expertise in biomanufacturing with the recent addition of Rahul Singhvi, MBA, ScD, CEO of National Resilience, Inc., as well as in gene therapy with the recent addition of Stewart Parker, MBA. We wish Pat well in all his future endeavors.”
“It has been an exciting time working with Codexis and seeing it transform into the company it is today,” said Dr. Yang. “The company is in great hands with this leadership team, and I look forward to watching their future successes across Life Sciences and Biotherapeutics.”
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of small molecule pharmaceuticals, in RNA and DNA synthesis and the creation of next generation life science tools, and as gene therapies and oral enzyme therapies. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved return on capital in manufacturing, improved sensitivity in genomic and diagnostic applications, and more efficacious therapeutics. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(781) 572-1147
media@codexis.com
FAQ
What led to Patrick Yang's decision not to seek re-election to the Codexis Board?
How long did Patrick Yang serve on the Codexis Board?
What are the implications of Patrick Yang's departure from Codexis?
Who has joined the Codexis Board recently?
